Technology
Cell Shuttle
Cartridge
Software
Services
IDMO Overview
IDMO Capabilities
IDMO Advantage
IDMO Smart Factories
Partnering
Existing TAP Partners
TAP Overview
Partner With Cellares
Company
Mission
Leadership
Board of Advisors
Board of Directors
Investors
Resources
Contact
Careers
Interdisciplinary Team
Culture & Values
Perks
Opportunities
News
Partner with us
Cellares
Technology
Cell Shuttle
Cartridge
Software
Services
IDMO Overview
IDMO Capabilities
IDMO Advantage
IDMO Smart Factories
Partnering
Existing TAP Partners
TAP Overview
Partner With Cellares
Company
Mission
Leadership
Board of Advisors
Board of Directors
Investors
Resources
Contact
Careers
Interdisciplinary Team
Culture & Values
Perks
Opportunities
News
Partner with us
October 06, 2022
Will Manufacturing Be the Stumbling Block for T-Cell Therapies?
Related News
March 26, 2024
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
March 12, 2024
Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence
November 06, 2023
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform